Synthesis and anti-HIV activity of N-(3-amino-3,4-dihydro-4-oxopyrimidin-2- yl)-4-chloro-2-mercapto-5-methylbenzenesulfonamide derivatives

Journal of Heterocyclic Chemistry

Volumn 44, Issue 1, 2007, Pages 261-267

  Brzozowski, Zdzisław ^a   Sa̧czewski, Franciszek ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

BENZENESULFONAMIDE DERIVATIVE; N (3 AMINO 3,4 DIHYDRO 4 OXOPYRIMIDIN 2 YL) 4 CHLORO 2 MERCAPTO 5 METHYLBENZENESULFONAMIDE DERIVATIVE; N [3 AMINO 3,4 DIHYDRO 6 (TERT BUTYL) 4 OXOTHIENO[2,3 E]PYRIMIDIN 2 YL] 4 CHLORO 2 MERCAPTO 5 METHYLBENZENESULFONAMIDE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG CYTOTOXICITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; IN VITRO STUDY; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION;

EID: 34548340454     PISSN: 0022152X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jhet.5570440144     Document Type: Article

References (24)

1. A. Scozzafava, and A. Mastrolorenzo, C.T. Supuran. Curr. Cancer Drug Targets, 1, 55 (2002).
2. A. Scozzafava, A, Casini and C. T. Supuran, Curr. Med. Chem., 9, 1167 (2002).
3. C.T. Supuran, A. Casini, A. Scozzafava, Med. Res. Rev., 5, 535 (2003).
4. A. Scozzafava, T. Owa, A. Mastrolorenzo, and C.T. Supuran, Curr. Med. Chem., 10, 925 (2003).
5. N. Masuda, O. Yamamoto, M. Fujii, T. Ohgami, J. Fujiysu, T. Kontani, A. Moritoma, M. Ortia, H. Kurihara, H. Koga, H. Nakahara, S. Kacjeyama, M. Ohto, H, Jnoue, T. Hatla, H. Suzuki, K. Sudo, Y. Shimzu, E. Kodama, M. Matsuoka, M. Fujiwara, T. Yokota, S. Shigeta and M. Baba, Bioorg. Med. Chem., 12, 6171 (2004).
6. E. Pomamacka, Acta Polon. Pharm. Drug Res., 55, 481 (1998).
7. Z. Brzozowski and A. Komicka, Acta Polon. Pharm. Drug Res., 56, 132 (1999).
8. Z. Brzozowski and F. Saczewski, Eur. J. Med. Chem., 37, 285 (2002).
9. J. Slawinski, Eur. J. Med. Chem., 38, 179 (2003).
10. J. Slawinski, P. Bednarski, R. Grunert and P. Reszka, Pol. J. Chem., 77, 53 (2003).
11. J. Sławiński, P. Bednarski and P. Reszka, Pol. J. Chem. 78, 369 (2004).
12. J. Sławiński and M. Gdaniec, Eur. J. Med. Chem., 39, 377 (2005).
13. C. L. Kuo, H. Assefa, S. Kamath, Z. Brzozowski, J. Sławiń ski, F. Sa̧czewski, J. K. Buolamwini and N. Neamati, J. Med. Chem., 47, 389 (2004).
14. Z. Brzozowski and F. Sa̧czewski, J. Med. Chem. 45, 430 (2002).
15. Z. Brzozowski, F. Sa̧czewski and M. Gdaniec, Bioorg. Med. Chem., 11, 3673 (2003).
16. Z. Brzozowski, F. Sa̧czewski and M. Gdaniec, Eur. J. Med. Chem., 38, 991 (2003).
17. Z. Brzozowski, F. Sa̧czewski, T. Sanchez, C. L. Kuo, M. Gdaniec and N. Neamati, Bioorg. Med. Chem., 12, 3663 (2004).
18. Z. Brzozowski, F. Sa̧czewski and N. Neamati, Bioorg. Med. Chem., 14, 2985. (2006).
19. N. Neamati, A. Mazumder, S. Sunder, J. M. Owen, R. J. Schultz and R. J. Pommier, Antimicrob. Agents Chemother., 8, 485 (1997).
20. M.-W. Ding, Y.-F. Chen and N.-Y. Huang, Eur. J. Org. Chem., 3872 (2004).
21. O. W. Wieslow, R. Kiser, D. Fine, J. Bader, R. H. Shoemaker and M. R. Boyd, J. Natl. Cancer Inst., 81, 577 (1989) 577.
22. The geometry of 14 was optimized by ab initio method at the 6-31G** level using Spartan 5.0 program package. Wavefunction, Inc., Irvine, CA 92715, 1998, installed on a Silicon Graphics O2 workstation..
23. S. T. Titmuss, P. A. Keller and R. Griffith, Bioorg. Med. Chem., 7, 1163 (1999).
24. Z. Brzozowski and J. Sławiński, Acta Polon. Pharm., 41, 133 (1984).